44282 Federal Register / Vol. 62, No. 161 / Wednesday, August 20, 1997 / Notices

(2) To exclude herself from serving in

any advisory capacity to the Public

Health Service (PHS), including but not

limited to service on any PHS advisory

committee, board, and/or peer review

committee, or as a consultant. Dr.

London is required to submit a letter to

• Chemical Senses requesting a

retraction of the following article:

London, J.A. ‘‘Optical recording of

activity in the hamster gustatory cortex

elicited by electrical stimulation of the

tongue.’’ Chemical Senses 15:137–143,

1990;

• Brain Research requesting a

retraction of the following article:

London, J.A., & Wehby, R.G.

‘‘Classification of inhibitory responses

of the hamster gustatory cortex.’’ Brain

Research 666:270–274, 1994; and

• Optical Methods in Neurobiology

requesting a retraction of Section V,

Results—Hamster of the following

article: London, J.A., & Cohen, L.B.

‘‘High time resolution, multi-site optical

measurement of vertebrate

somatosensory cortex during

epileptiform discharges and vertebrate

gustatory cortex.’’ Optical Methods in

Neurobiology, pp. 61–78, 1988,

prepared for the 11th Annual Meeting of

the European Neuroscience Association.

FOR FURTHER INFORMATION CONTACT:

Acting Director, Division of Research

Investigations, Office of Research

Integrity, 5515 Security Lane, Suite 700,

Rockville, MD 20852, (301) 443–5330.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 97–22081 Filed 8–19–97; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 97F–0301]

Ube Industries (America), Inc.; Filing of

Food Additive Petition; Correction

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug

Administration (FDA) is correcting a

notice that appeared in the Federal

Register of July 21, 1997 (62 FR 39003).

The document announced that Ube

Industries (America), Inc., filed a

petition proposing that the food additive

regulations be amended to change the

melting point range specifications for

Nylon 6/66 resins intended for use in

contact with food. The document

published with an incorrect docket

number. This document corrects that

error.

FOR FURTHER INFORMATION CONTACT: Vir

D. Anand, Center for Food Safety and

Applied Nutrition (HFS–215), Food and

Drug Administration, 200 C St. SW.,

Washington, DC 20204, 202–418–3081.

In FR Doc. 97–19127, appearing on

page 39003 in the Federal Register of

Monday, July 21, 1997, the following

correction is made:

1. On page 39003, in the first column,

Docket No. ‘‘97N–0301’’ is corrected to

read ‘‘97F–0301’’.

Dated: August 13, 1997.

William K. Hubbard,

Associate Commissioner for Policy

Coordination.

[FR Doc. 97–22091 Filed 8–19–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). The meeting will be open to the

public.

Name of Committee: Anesthetic and

Life Support Drugs Advisory

Committee.

General Function of the Committee:

To provide advice and

recommendations to the agency on FDA

regulatory issues.

Date and Time: The meeting will be

held on September 17, 1997, 8 a.m. to

5 p.m.

Location: Gaithersburg Hilton, Grand

Ballroom, 620 Perry Pkwy.,

Gaithersburg, MD.

Contact Person: Karen M. TempletonSomers or Robin M. Spencer, Center for

Drug Evaluation and Research (HFD–

21), Food and Drug Administration,

5600 Fishers Lane, Rockville, MD

20857, 301–443–5455, or FDA Advisory

Committee Information Line, 1–800–

741–8138 (301–443–0572 in the

Washington, DC area), code 12529.

Please call the Information Line for upto-date information on this meeting.

Agenda: The committee will hear

presentations and discuss data

submitted regarding new drug

application (NDA) 20–747, ActiqTM (oral

transmucosal fentanyl citrate, drug

matrix on a handle), Anesta Corp., for

the management of chronic pain,

particularly breakthrough pain, in

patients who are already receiving and

are tolerant to opioid therapy.

Procedure: Interested persons may

present data, information, or views,

orally or in writing, on issues pending

before the committee. Written

submissions may be made to the contact

person by September 4, 1997. Oral

presentations from the public will be

scheduled between approximately 8

a.m. and 8:30 a.m. and 3 p.m. and 3:30

p.m. Time allotted for each presentation

may be limited. Those desiring to make

formal oral presentations should notify

the contact person before September 4,

1997, and submit a brief statement of

the general nature of the evidence or

arguments they wish to present, the

names and addresses of proposed

participants, and an indication of the

approximate time requested to make

their presentation.

Notice of this meeting is given under

the Federal Advisory Committee Act (5

U.S.C. app. 2).

Dated: August 14, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97–22090 Filed 8–19–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). The meeting will be open to the

public.

Name of Committee: Blood Products

Advisory Committee.

General Function of the Committee:

To provide advice and

recommendations to the agency on FDA

regulatory issues.

Date and Time: The meeting will be

held on September 18, 1997, 8 a.m. to

5:30 p.m., and September 19, 1997, 8

a.m. to 4 p.m.

Location: Quality Suites Hotel,

Potomac Rooms I, II, and III, Three

Research Ct. (off Shady Grove Rd.),

Rockville, MD.

Contact Person: Linda A. Smallwood,

Center for Biologics Evaluation and

Research (HFM–350), Food and Drug

Administration, 1401 Rockville Pike,

Rockville, MD 20852, 301–827–3514, or

FDA Advisory Committee Information
Federal Register / Vol. 62, No. 161 / Wednesday, August 20, 1997 / Notices 44283

Line, 1–800–741–8138 (301–443–0572

in the Washington, DC area), code

12388. Please call the Information Line

for up-to-date information on this

meeting.

Agenda: On the morning of

September 18, 1997, the committee will

discuss the topic of inadvertent

contamination of plasma. In the

afternoon, the committee will hear a

proposal for management of plasma and

plasma donors presented by the

International Plasma Products Industry

Association. On September 19, 1997, the

committee will discuss the topic of

cryoprecipitate-depleted plasma.

Procedure: Interested persons may

present data, information, or views,

orally or in writing, on issues pending

before the committee. Written

submissions may be made to the contact

person by September 10, 1997. Oral

presentations from the public will be

scheduled between approximately 11

a.m. and 11:30 a.m. and 2 p.m. and 3

p.m. on September 18, 1997. Time

allotted for each presentation may be

limited. Those desiring to make formal

oral presentations should notify the

contact person before September 10,

1997, and submit a brief statement of

the general nature of the evidence or

arguments they wish to present, the

names and addresses of proposed

participants, and an indication of the

approximate time requested to make

their presentation.

Notice of this meeting is given under

the Federal Advisory Committee Act (5

U.S.C. app. 2).

Dated: August 14, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97–22088 Filed 8–19–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). The meeting will be open to the

public.

Name of Committee: Circulatory

System Devices Panel of the Medical

Devices Advisory Committee.

General Function of the Committee:

To provide advice and

recommendations to the agency on FDA

regulatory issues.

Date and Time: The meeting will be

held on September 15, 1997, 9:30 a.m.

to 6 p.m., and September 16, 1997, 8:30

a.m. to 3 p.m.

Location: Gaithersburg Hilton, Salons

A, B, and C of the Ballroom, 620 Perry

Pkwy., Gaithersburg, MD.

Contact Person: John E. Stuhlmuller,

Center for Devices and Radiological

Health (HFZ–450), Food and Drug

Administration, 9200 Corporate Blvd.,

Rockville, MD 20850, 301–443–8243,

ext. 157, or FDA Advisory Committee

Information Line, 1–800–741–8138

(301–443–0572 in the Washington, DC

area), code 12625. Please call the

Information Line for up-to-date

information on this meeting.

Agenda: On September 15, 1997, the

committee will hear a presentation of

the basic concepts of FDA’s Product

Development Process. The committee

will discuss and make

recommendations on two premarket

approval (PMA) applications for

prosthetic heart valves. On September

16, 1997, the committee will discuss

and make recommendations on a PMA

for a prosthetic heart valve.

Procedure: Interested persons may

present data, information, or views,

orally or in writing, on issues pending

before the committee. Written

submissions may be made to the contact

person by September 5, 1997. Oral

presentations from the public will be

scheduled between approximately 9:30

a.m. and 10:30 a.m. on September 15,

1997, and between approximately 8:30

a.m. and 9:30 a.m. on September 16,

1997. Time allotted for each

presentation may be limited. Those

desiring to make formal oral

presentations should notify the contact

person before September 5, 1997, and

submit a brief statement of the general

nature of the evidence or arguments

they wish to present, the names and

addresses of proposed participants, and

an indication of the approximate time

requested to make their presentation.

Notice of this meeting is given under

the Federal Advisory Committee Act (5

U.S.C. app. 2).

Dated: August 14, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97–22089 Filed 8–19–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Health Care Financing Administration

[Form #HCFA–1500, OMB #0938–0008]

Emergency Clearance: Public

Information Collection Requirements

Submitted to the Office of Management

and Budget (OMB)

In compliance with the requirement

of section 3506(c)(2)(A) of the

Paperwork Reduction Act of 1995, the

Health Care Financing Administration

(HCFA), Department of Health and

Human Services (DHHS), has submitted

to the Office of Management and Budget

(OMB) the following request for

Emergency review. We are requesting an

emergency review because the

collection of this information is needed

prior to the expiration of the normal

time limits under OMB’s regulations at

5 CFR Part 1320. The HCFA–1500 is

used to determine proper payment for

certain Medicare services rendered to

Medicare beneficiaries. Without this

information HCFA would not be able to

obtain the information necessary to

reimburse providers. The Agency

cannot reasonably comply with the

normal clearance procedures because

public harm is likely to result due to the

possibility of providers not rendering

services to Medicare beneficiaries due to

the possibility of non-payment.

HCFA is requesting OMB review and

approval of this collection by 09/01/97,

with a 180-day approval period. During

this 180-day period HCFA will publish

a separate Federal Register notice

announcing the initiation of an

extensive 60-day agency review and

public comment period on these

requirements. Then HCFA will submit

the requirements for OMB review and

an extension of this emergency

approval. In this submission HCFA will

respond as appropriate to the public

comments received in response to the

10/24/97 Federal Register notice

requesting public comment on the

continued use of the HCFA–1500 and

related data.

1. Type of Information Collection

Request: Extension of a currently

approved collection, without change;

Title of Information Collection:

Medicare/Medicaid Health Insurance

Common Claim Form and Instructions,

and Supporting Regulations 42 CFR

424.32 (Basic Requirements for all

Claims) and 42 CFR 414.40 (Coding and

Ancillary Policies); Form No.: HCFA–

1500 (OMB #0938–0008); Use: This form

and instructions are standardized for

use in the Medicare/Medicaid programs

to apply for reimbursement for covered